Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Feb;73(4):420–423. doi: 10.1038/bjc.1996.75

High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci.

J Devlin 1, P A Elder 1, H Gabra 1, C M Steel 1, M A Knowles 1
PMCID: PMC2074458  PMID: 8595153

Abstract

We have screened 33 ovarian tumours of various grades and stages for the loss of heterozygosity (LOH) of markers on chromosome 9. LOH was detected in 26 cases (79%). Eleven tumours (33%) showed LOH of all informative markers. The remaining 15 cases had partial deletions. Of these, six (18%) had losses on 9p only, three (9%) had LOH confined to 9q and six (18%) had losses on both chromosome arms, four of which had a retention of hetereozygosity in between. There was no association between tumour grade stage or histopathology and any losses. High-density deletion mapping was carried out in 12 selected cases that had partial deletions of 9p and/or 9q. The deleted region on 9p included the cyclin-dependent kinase inhibitor 2 (CDKN2) locus and one tumour was found to have a homozygous deletion of CDKN2. LOH on 9q extended over a larger region. We found evidence for two regions of deletion on 9q, one at 9q34 and the other encompassing the nevoid basal cell carcinoma (Gorlin) syndrome locus on proximal 9q.

Full text

PDF
420

Images in this article

422Figure 2
on p.422

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cairns P., Tokino K., Eby Y., Sidransky D. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res. 1994 Mar 15;54(6):1422–1424. [PubMed] [Google Scholar]
  2. Cairns P., Tokino K., Eby Y., Sidransky D. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res. 1995 Jan 15;55(2):224–227. [PubMed] [Google Scholar]
  3. Carbonara C., Longa L., Grosso E., Borrone C., Garrè M. G., Brisigotti M., Migone N. 9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene. Hum Mol Genet. 1994 Oct;3(10):1829–1832. doi: 10.1093/hmg/3.10.1829. [DOI] [PubMed] [Google Scholar]
  4. Chenevix-Trench G., Kerr J., Friedlander M., Hurst T., Sanderson B., Coglan M., Ward B., Leary J., Khoo S. K. Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors. Am J Hum Genet. 1994 Jul;55(1):143–149. [PMC free article] [PubMed] [Google Scholar]
  5. Cliby W., Ritland S., Hartmann L., Dodson M., Halling K. C., Keeney G., Podratz K. C., Jenkins R. B. Human epithelial ovarian cancer allelotype. Cancer Res. 1993 May 15;53(10 Suppl):2393–2398. [PubMed] [Google Scholar]
  6. Devlin J., Keen A. J., Knowles M. A. Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA. Oncogene. 1994 Sep;9(9):2757–2760. [PubMed] [Google Scholar]
  7. Eccles D. M., Cranston G., Steel C. M., Nakamura Y., Leonard R. C. Allele losses on chromosome 17 in human epithelial ovarian carcinoma. Oncogene. 1990 Oct;5(10):1599–1601. [PubMed] [Google Scholar]
  8. Fountain J. W., Karayiorgou M., Ernstoff M. S., Kirkwood J. M., Vlock D. R., Titus-Ernstoff L., Bouchard B., Vijayasaradhi S., Houghton A. N., Lahti J. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10557–10561. doi: 10.1073/pnas.89.21.10557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Habuchi T., Devlin J., Elder P. A., Knowles M. A. Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene. 1995 Oct 19;11(8):1671–1674. [PubMed] [Google Scholar]
  10. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., 3rd, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994 Apr 15;264(5157):436–440. doi: 10.1126/science.8153634. [DOI] [PubMed] [Google Scholar]
  11. Keen A. J., Knowles M. A. Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene. 1994 Jul;9(7):2083–2088. [PubMed] [Google Scholar]
  12. Merlo A., Gabrielson E., Mabry M., Vollmer R., Baylin S. B., Sidransky D. Homozygous deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in primary human small cell lung cancer. Cancer Res. 1994 May 1;54(9):2322–2326. [PubMed] [Google Scholar]
  13. Migeon B. R. Short arm deletions in group E and chromosomal "deletion" syndromes. J Pediatr. 1966 Sep;69(3):432–438. doi: 10.1016/s0022-3476(66)80088-4. [DOI] [PubMed] [Google Scholar]
  14. Nobori T., Miura K., Wu D. J., Lois A., Takabayashi K., Carson D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994 Apr 21;368(6473):753–756. doi: 10.1038/368753a0. [DOI] [PubMed] [Google Scholar]
  15. Osborne R. J., Leech V. Polymerase chain reaction allelotyping of human ovarian cancer. Br J Cancer. 1994 Mar;69(3):429–438. doi: 10.1038/bjc.1994.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Povey S., Armour J., Farndon P., Haines J. L., Knowles M., Olopade F., Pilz A., White J. A., Kwiatkowski D. J. Report and abstracts of the Third International Workshop on Chromosome 9. Cambridge, United Kingdom, 9-11 April, 1994. Ann Hum Genet. 1994 Jul;58(Pt 3):177–250. doi: 10.1111/j.1469-1809.1994.tb01887.x. [DOI] [PubMed] [Google Scholar]
  17. Quinn A. G., Sikkink S., Rees J. L. Delineation of two distinct deleted regions on chromosome 9 in human non-melanoma skin cancers. Genes Chromosomes Cancer. 1994 Dec;11(4):222–225. doi: 10.1002/gcc.2870110404. [DOI] [PubMed] [Google Scholar]
  18. Schultz D. C., Vanderveer L., Buetow K. H., Boente M. P., Ozols R. F., Hamilton T. C., Godwin A. K. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res. 1995 May 15;55(10):2150–2157. [PubMed] [Google Scholar]
  19. Shanley S. M., Dawkins H., Wainwright B. J., Wicking C., Heenan P., Eldon M., Searle J., Chenevix-Trench G. Fine deletion mapping on the long arm of chromosome 9 in sporadic and familial basal cell carcinomas. Hum Mol Genet. 1995 Jan;4(1):129–133. doi: 10.1093/hmg/4.1.129. [DOI] [PubMed] [Google Scholar]
  20. Williamson M. P., Elder P. A., Shaw M. E., Devlin J., Knowles M. A. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet. 1995 Sep;4(9):1569–1577. doi: 10.1093/hmg/4.9.1569. [DOI] [PubMed] [Google Scholar]
  21. van der Riet P., Nawroz H., Hruban R. H., Corio R., Tokino K., Koch W., Sidransky D. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res. 1994 Mar 1;54(5):1156–1158. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES